グレカプレビル/ピブレンタスビル治療はゲノタイプ2型C型慢性肝疾患に対するソフォスブビル＋リバビリン治療のウイルス学的無効例に有効である

DOI Web Site Web Site 被引用文献1件 参考文献3件

書誌事項

タイトル別名
  • Efficacy and Safety of Glecaprevir/Pibrentasvir Combination Therapy for Patients with Genotype 2 Chronic Hepatitis C Infection Who Failed HCV Eradication by SOF+RBV Treatment
  • グレカプレビル/ピブレンタスビル チリョウ ワ ゲノタイプ 2ガタ Cガタ マンセイ カン シッカン ニ タイスル ソフォスブビル+リバビリン チリョウ ノ ウイルスガクテキ ムコウレイ ニ ユウコウ デ アル

この論文をさがす

抄録

<p>Although sofosbuvir plus ribavirin (SOF+RBV) treatment is highly effective for genotype 2 chronic hepatitis C infection, 3%-7% of patients failed to achieve a sustained virologic response (SVR). As the optimal combination of direct-acting antivirals remains unclear, we conducted a multicenter trial using 12-week Glecaprevir/Pibrentasvir (GLE/PIB) therapy for patients who failed to achieve an SVR by SOF+RBV treatment. We encountered 13 patients; 9 men and 4 women. Of 13 patients, 10 were genotype 2a and 3 were genotype 2b. The rates of rapid virologic response, expected treatment response, and SVR12 were 92.3%, 100%, and 100%, respectively. Adverse events were observed in 4 cases (30.8%), which were mild events. In conclusion, 12-week GLE/PIB therapy is highly effective for patients who did not achieve SVR by SOF+RBV treatment.</p>

収録刊行物

  • 肝臓

    肝臓 60 (2), 77-79, 2019-02-20

    一般社団法人　日本肝臓学会

被引用文献 (1)*注記

もっと見る

参考文献 (3)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ